The results of these clinical trials indicated that SGLT2 inhibitors, including empagliflozin, canagliflozin, and dapagliflozin, lead to a significant reduction in the composite outcomes of myocardial infarction, stroke, and CV death and/or hospitalization for heart failure (HF) in patients with T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.